Skip to main content

Table 1 Distribution of ATAD2 and Clinicopathological Characteristics in HCC patients

From: miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis

Characteristics Number of patients ATAD2 overexpression Negative or weak expression P
Total cases 129 83 46  
Age (years)     
 ≥60 54 34(63.0%) 20(37.0%) 0.782
 <60 75 49(65.3%) 26(34.7%)
Gender     
 Male 106 69(65.1%) 37(34.9%) 0.701
 Female 23 14(60.9%) 9(39.1%)
Tumor size     
 ≥ 5cm 83 53(63.9%) 30(36.1%) 0.877
 < 5cm 46 30(65.2%) 16(34.8%)
Metastasis     
 Yes 72 54(75%) 18(25%) 0.005
 No 57 29(50.9%) 28(49.1%)
HBsAg status     
 Positive 73 43(58.9%) 30(41.1%) 0.141
 Negative 56 40(71.4%) 16(28.6%)
Tumor differentiation     
 WD 54 34(63.0%) 20(37.0%) 0.955
 MD 60 39(65.0%) 21(35.0%)
 PD 15 10(66.7%) 5(33.3%)
Cirrhosis     
 Yes 86 58(67.4%) 28(32.6%) 0.298
 No 43 25(58.1%) 18(41.9%)
Serum AFP     
 <200 ng/dl 41 29(70.7%) 12(29.3%) 0.301
 ≥200 ng/dl 88 54(61.4%) 34(38.6%)
Tumor stage     
 TNM I+II 42 25(59.5%) 17(40.5%) 0.427
 TNM III+IV 87 58(66.7%) 29(33.3%)